ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference

August 31, 2021 GMT

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Aug 31, 2021--

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the 23 rd Annual H.C. Wainwright Global Investment Conference. The presentation will be available on demand beginning at 7:00am ET on Monday, September 13, 2021.

Interested parties can access the live and archived webcast of the event on the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

ADVERTISEMENT

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

ADVERTISEMENT

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210831005874/en/

CONTACT: Investor Contact:

John Sharp

PhaseBio Pharmaceuticals, Inc.

Chief Financial Officer

(610) 981-6506

john.sharp@phasebio.comMedia Contact:

Will Zasadny

Canale Communications, Inc.

will.zasadny@canalecomm.com

(619) 961-8848

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA PENNSYLVANIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CARDIOLOGY

SOURCE: PhaseBio Pharmaceuticals, Inc.

Copyright Business Wire 2021.

PUB: 08/31/2021 04:00 PM/DISC: 08/31/2021 04:01 PM

http://www.businesswire.com/news/home/20210831005874/en